Cargando…

Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population

Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor format...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamstrup, Peter, Sand, Jannie Marie Bülow, Ulrik, Charlotte Suppli, Janner, Julie, Rønn, Christian Philip, Rønnow, Sarah Rank, Leeming, Diana Julie, Jensen, Sidse Graff, Wilcke, Torgny, Mathioudakis, Alexander G., Miravitlles, Marc, Lapperre, Therese, Bendstrup, Elisabeth, Frikke-Schmidt, Ruth, Murray, Daniel D., Itenov, Theis, Bossios, Apostolos, Nielsen, Susanne Dam, Vestbo, Jørgen, Biering-Sørensen, Tor, Karsdal, Morten, Jensen, Jens-Ulrik, Sivapalan, Pradeesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405886/
https://www.ncbi.nlm.nih.gov/pubmed/36009558
http://dx.doi.org/10.3390/biomedicines10082011
_version_ 1784773987410116608
author Kamstrup, Peter
Sand, Jannie Marie Bülow
Ulrik, Charlotte Suppli
Janner, Julie
Rønn, Christian Philip
Rønnow, Sarah Rank
Leeming, Diana Julie
Jensen, Sidse Graff
Wilcke, Torgny
Mathioudakis, Alexander G.
Miravitlles, Marc
Lapperre, Therese
Bendstrup, Elisabeth
Frikke-Schmidt, Ruth
Murray, Daniel D.
Itenov, Theis
Bossios, Apostolos
Nielsen, Susanne Dam
Vestbo, Jørgen
Biering-Sørensen, Tor
Karsdal, Morten
Jensen, Jens-Ulrik
Sivapalan, Pradeesh
author_facet Kamstrup, Peter
Sand, Jannie Marie Bülow
Ulrik, Charlotte Suppli
Janner, Julie
Rønn, Christian Philip
Rønnow, Sarah Rank
Leeming, Diana Julie
Jensen, Sidse Graff
Wilcke, Torgny
Mathioudakis, Alexander G.
Miravitlles, Marc
Lapperre, Therese
Bendstrup, Elisabeth
Frikke-Schmidt, Ruth
Murray, Daniel D.
Itenov, Theis
Bossios, Apostolos
Nielsen, Susanne Dam
Vestbo, Jørgen
Biering-Sørensen, Tor
Karsdal, Morten
Jensen, Jens-Ulrik
Sivapalan, Pradeesh
author_sort Kamstrup, Peter
collection PubMed
description Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65–1.48), VWF-N: HR 1.56 (95% CI 1.07–2.27), and VWF-A: HR 0.78 (95% CI 0.52–1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population.
format Online
Article
Text
id pubmed-9405886
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94058862022-08-26 Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population Kamstrup, Peter Sand, Jannie Marie Bülow Ulrik, Charlotte Suppli Janner, Julie Rønn, Christian Philip Rønnow, Sarah Rank Leeming, Diana Julie Jensen, Sidse Graff Wilcke, Torgny Mathioudakis, Alexander G. Miravitlles, Marc Lapperre, Therese Bendstrup, Elisabeth Frikke-Schmidt, Ruth Murray, Daniel D. Itenov, Theis Bossios, Apostolos Nielsen, Susanne Dam Vestbo, Jørgen Biering-Sørensen, Tor Karsdal, Morten Jensen, Jens-Ulrik Sivapalan, Pradeesh Biomedicines Article Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65–1.48), VWF-N: HR 1.56 (95% CI 1.07–2.27), and VWF-A: HR 0.78 (95% CI 0.52–1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population. MDPI 2022-08-19 /pmc/articles/PMC9405886/ /pubmed/36009558 http://dx.doi.org/10.3390/biomedicines10082011 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kamstrup, Peter
Sand, Jannie Marie Bülow
Ulrik, Charlotte Suppli
Janner, Julie
Rønn, Christian Philip
Rønnow, Sarah Rank
Leeming, Diana Julie
Jensen, Sidse Graff
Wilcke, Torgny
Mathioudakis, Alexander G.
Miravitlles, Marc
Lapperre, Therese
Bendstrup, Elisabeth
Frikke-Schmidt, Ruth
Murray, Daniel D.
Itenov, Theis
Bossios, Apostolos
Nielsen, Susanne Dam
Vestbo, Jørgen
Biering-Sørensen, Tor
Karsdal, Morten
Jensen, Jens-Ulrik
Sivapalan, Pradeesh
Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
title Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
title_full Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
title_fullStr Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
title_full_unstemmed Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
title_short Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
title_sort biomarkers of clot activation and degradation and risk of future major cardiovascular events in acute exacerbation of copd: a cohort sub-study in a randomized trial population
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405886/
https://www.ncbi.nlm.nih.gov/pubmed/36009558
http://dx.doi.org/10.3390/biomedicines10082011
work_keys_str_mv AT kamstruppeter biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT sandjanniemariebulow biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT ulrikcharlottesuppli biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT jannerjulie biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT rønnchristianphilip biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT rønnowsarahrank biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT leemingdianajulie biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT jensensidsegraff biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT wilcketorgny biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT mathioudakisalexanderg biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT miravitllesmarc biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT lapperretherese biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT bendstrupelisabeth biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT frikkeschmidtruth biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT murraydanield biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT itenovtheis biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT bossiosapostolos biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT nielsensusannedam biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT vestbojørgen biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT bieringsørensentor biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT karsdalmorten biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT jensenjensulrik biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation
AT sivapalanpradeesh biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation